CHMP recommends Amuvttra to treat hereditary transthyretin-mediated (hATTR) amyloidosis
Alnylam Pharmaceuticals, Inc., has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of vutrisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy
If approved by the European Commission (EC), vutrisiran will be commercialized under the brand name Amuvttra as the first and only treatment option to demonstrate reversal in neuropathy impairment with subcutaneous administration once every three months.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.